The latest update is out from Akero Therapeutics Inc (AKRO).
Akero Therapeutics has announced promising 96-week results from its Phase 2b HARMONY study, showing significant improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH) using their drug candidate, efruxifermin (EFX). The study revealed a remarkable increase in the rate of fibrosis improvement, with the 50mg EFX dose showing a response rate of 75%, a significant advance from the 24-week results. The drug’s safety profile remains positive, with no deaths reported and most adverse events being mild and transient. These findings bolster the potential of EFX in treating MASH, especially in patients with more advanced fibrosis. Additional results from the SYMMETRY study on compensated cirrhosis are expected in early 2025.
Learn more about AKRO stock on TipRanks’ Stock Analysis page.
